Thanks to its benefits, trainees can accumulate greater training volumes, potentially creating more significant muscle disruptions for better growth and strength gain
*Correspondence: Yanjun Li, [email protected] These authors have contributed equally to this work and share first authorship Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
To achieve sufficient volume, we aimed at receiving 100 questionnaires
Despite the numerous theories that have been proffered to explain the development of adenomyosis, our current understanding of disease pathogenesis remains limited
The ChEMBL drug registry records tirzepatide at maximum phase 4 (approved), first approval 2022, parenteral, with a first-in-class GIP-agonist designation and a boxed-warning flag